deltatrials
Terminated PHASE4 INTERVENTIONAL 1-arm NCT04955990

A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants (CARE PAH)

An International, Non-Drug Interventional, Real-world Cohort of PAH Patients Newly Initiating PAH Therapy With Guideline-directed Assessments of Disease Severity

Sponsor: Actelion

Interventions PAH Therapies
Updated 20 times since 2021 Last updated: Jan 31, 2025 Started: Oct 14, 2021 Primary completion: Dec 20, 2022 Completion: Dec 20, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The sponsor decided to terminate the study.

Listed as NCT04955990, this PHASE4 trial focuses on Pulmonary Arterial Hypertension and remains terminated or withdrawn. Sponsored by Actelion, it has been updated 20 times since 2021, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Jan 2022 · 3 months · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~May 2023 · 3 months · monthly snapshot~May 2023 – ~Apr 2024 · 11 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Mar 2025 · 6 months · monthly snapshot~Mar 2025 – ~Sep 2025 · 6 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

20 versions recorded
  1. Sep 2025 — Present [monthly]

    Terminated PHASE4

  2. Mar 2025 — Sep 2025 [monthly]

    Terminated PHASE4

  3. Sep 2024 — Mar 2025 [monthly]

    Terminated PHASE4

  4. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE4

  5. Apr 2024 — Jul 2024 [monthly]

    Terminated PHASE4

Show 15 earlier versions
  1. May 2023 — Apr 2024 [monthly]

    Terminated PHASE4

    Status: RecruitingTerminated

  2. Feb 2023 — May 2023 [monthly]

    Recruiting PHASE4

  3. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE4

  4. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE4

  5. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE4

  6. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE4

  7. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE4

  8. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE4

  9. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE4

  10. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE4

  11. Mar 2022 — Apr 2022 [monthly]

    Recruiting PHASE4

  12. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE4

  13. Jan 2022 — Feb 2022 [monthly]

    Recruiting PHASE4

    Status: Not Yet RecruitingRecruiting

  14. Oct 2021 — Jan 2022 [monthly]

    Not Yet Recruiting PHASE4

  15. Sep 2021 — Oct 2021 [monthly]

    Not Yet Recruiting PHASE4

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Actelion
Data source: Actelion

For direct contact, visit the study record on ClinicalTrials.gov .